Read More
NCAA’s landmark deal to pay college athletes on hold after hearing
Related Posts
Rucaparib-Nivolumab Maintenance Not the Answer in Newly Diagnosed Ovarian Cancer
Meeting Coverage > ESMO — Poorer survival outcomes plus more toxicity versus rucaparib alone by Charles Bankhead, Senior Editor, MedPage Today September 18, 2024 Adding a PD-1 inhibitor to PARP inhibitor maintenance therapy failed to slow progression or improve survival in newly diagnosed advanced ovarian cancer, a large randomized trial showed. In fact, median progression-free
What do advertisers want from Tubi in the U.K.?
When Tubi made its debut in the U.K. nearly two months ago, everyone expected it to make a splash with advertisers. Given its impressive track record of outpacing some hefty competitors in the past 18 months, the bar was set high. However, the reality has been more of a gentle ripple than a tidal wave.
